Laverman GD - Search Results

1

Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.

de Jong MA, Petrykiv SI, Laverman GD, van Herwaarden AE, de Zeeuw D, Bakker SJL, Heerspink HJL, de Borst MH. de Jong MA, et al. Among authors: laverman gd. Clin J Am Soc Nephrol. 2019 Jan 7;14(1):66-73. doi: 10.2215/CJN.04530418. Epub 2018 Dec 17. Clin J Am Soc Nephrol. 2019. PMID: 30559106 Free PMC article. Clinical Trial.

2

Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria.

Laverman GD, Henning RH, de Jong PE, Navis G, de Zeeuw D. Laverman GD, et al. Am J Kidney Dis. 2001 Dec;38(6):1381-4. doi: 10.1053/ajkd.2001.29262. Am J Kidney Dis. 2001. PMID: 11728979 Clinical Trial.

3

Dual renin-angiotensin system blockade at optimal doses for proteinuria.

Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Laverman GD, et al. Kidney Int. 2002 Sep;62(3):1020-5. doi: 10.1046/j.1523-1755.2002.00536.x. Kidney Int. 2002. PMID: 12164886 Free article. Clinical Trial.

4

Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes.

Laverman GD, Van Goor H, Henning RH, De Jong PE, De Zeeuw D, Navis G. Laverman GD, et al. Kidney Int. 2003 Jan;63(1):64-71. doi: 10.1046/j.1523-1755.2003.00708.x. Kidney Int. 2003. PMID: 12472769 Free article.

5

Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?

Laverman GD, de Zeeuw D, Navis G. Laverman GD, et al. J Renin Angiotensin Aldosterone Syst. 2002 Dec;3(4):205-13. doi: 10.3317/jraas.2002.042. J Renin Angiotensin Aldosterone Syst. 2002. PMID: 12584664 Free article. Review.

6

The COOPERATE trial.

Vogt L, Laverman GD, de Zeeuw D, Navis G. Vogt L, et al. Among authors: laverman gd. Lancet. 2003 Mar 22;361(9362):1055-6. doi: 10.1016/S0140-6736(03)12803-6. Lancet. 2003. PMID: 12660079 No abstract available.

7

Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats.

Bos H, Laverman GD, Henning RH, Tiebosch AT, de Jong PE, de Zeeuw D, Navis G. Bos H, et al. Among authors: laverman gd. J Renin Angiotensin Aldosterone Syst. 2003 Jun;4(2):106-12. doi: 10.3317/jraas.2003.010. J Renin Angiotensin Aldosterone Syst. 2003. PMID: 12806593 Free article.

8

ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection?

Laverman GD, Remuzzi G, Ruggenenti P. Laverman GD, et al. J Am Soc Nephrol. 2004 Jan;15 Suppl 1:S64-70. doi: 10.1097/01.asn.0000093368.27046.3c. J Am Soc Nephrol. 2004. PMID: 14684676 Review.

9

Renoprotection with and without blood pressure reduction.

Laverman GD, Andersen S, Rossing P, Navis G, de Zeeuw D, Parving HH. Laverman GD, et al. Kidney Int Suppl. 2005 Apr;(94):S54-9. doi: 10.1111/j.1523-1755.2005.09414.x. Kidney Int Suppl. 2005. PMID: 15752241 Free article. Clinical Trial.

10

Optimal dosing of renin-angiotensin-aldosterone system blockers for renal protection: a solved issue?

Laverman GD, Bakker SJ, Navis GJ. Laverman GD, et al. Diabetologia. 2009 Jun;52(6):1217-8. doi: 10.1007/s00125-009-1328-5. Epub 2009 Mar 18. Diabetologia. 2009. PMID: 19294362 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters